Development of Thiabendazole-Loaded Mesoporous Silica Nanoparticles for Cancer Therapy

Volume: 8, Issue: 10, Pages: 4153 - 4162
Published: May 30, 2021
Abstract
Thiabendazole (TBZ) is an anthelmintic drug currently studied for anticancer purposes. However, due to its low solubility, its biomedical application has been limited. Using mesoporous silica nanoparticles (MSNPs), such as Mobil Composition of Matter Number 41 (MCM-41), as a drug carrier, is a promising approach to improve the solubility of low water-soluble drugs. In the present work, we aim to develop TBZ-loaded MCM-41 (TBZ MCM-41)...
Paper Details
Title
Development of Thiabendazole-Loaded Mesoporous Silica Nanoparticles for Cancer Therapy
Published Date
May 30, 2021
Journal
Volume
8
Issue
10
Pages
4153 - 4162
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.